Viridian Therapeutics, Inc. (VRDN)
19.00
-0.40
(-2.09%)
USD |
NASDAQ |
Oct 05, 16:00
19.00
0.00 (0.00%)
After-Hours: 17:49
Viridian Therapeutics Net Income (Quarterly) : -127.12M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -127.12M |
| March 31, 2026 | -104.90M |
| December 31, 2025 | -101.98M |
| September 30, 2025 | -34.60M |
| June 30, 2025 | -100.74M |
| March 31, 2025 | -86.91M |
| December 31, 2024 | -64.65M |
| September 30, 2024 | -76.69M |
| June 30, 2024 | -64.99M |
| March 31, 2024 | -48.54M |
| December 31, 2023 | -66.86M |
| September 30, 2023 | -47.66M |
| June 30, 2023 | -55.06M |
| March 31, 2023 | -68.15M |
| December 31, 2022 | -45.78M |
| September 30, 2022 | -28.90M |
| June 30, 2022 | -29.49M |
| March 31, 2022 | -25.69M |
| December 31, 2021 | -28.95M |
| September 30, 2021 | -14.04M |
| June 30, 2021 | -17.96M |
| March 31, 2021 | -18.46M |
| December 31, 2020 | -90.74M |
| September 30, 2020 | -5.494M |
| June 30, 2020 | -6.435M |
| Date | Value |
|---|---|
| March 31, 2020 | -8.044M |
| December 31, 2019 | -10.12M |
| September 30, 2019 | -11.23M |
| June 30, 2019 | -8.896M |
| March 31, 2019 | -11.63M |
| December 31, 2018 | -10.32M |
| September 30, 2018 | -9.011M |
| June 30, 2018 | -8.714M |
| March 31, 2018 | -4.661M |
| December 31, 2017 | -6.386M |
| September 30, 2017 | -5.834M |
| June 30, 2017 | -7.312M |
| March 31, 2017 | -6.985M |
| December 31, 2016 | -5.986M |
| September 30, 2016 | -4.166M |
| June 30, 2016 | -2.507M |
| March 31, 2016 | -2.758M |
| December 31, 2015 | -2.98M |
| September 30, 2015 | -3.152M |
| June 30, 2015 | -2.562M |
| March 31, 2015 | -2.634M |
| December 31, 2014 | -2.258M |
| September 30, 2014 | -1.637M |
| June 30, 2014 | -3.289M |
| December 31, 2013 | -0.2032M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
| Biogen, Inc. | 97.50M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.284M |
| Total Expenses (Quarterly) | 127.40M |
| EPS Diluted (Quarterly) | -1.178 |
| Enterprise Value | 1.556B |
| Gross Profit Margin (Quarterly) | 58.80% |
| Profit Margin (Quarterly) | -44.76K% |
| Earnings Yield | -19.52% |
| Normalized Earnings Yield | -19.73 |